The ARFGAP2 Knockout Jurkat Polyclonal Cells represent a CRISPR/Cas9-edited polyclonal knockout cell population derived from the Jurkat human T-lymphocyte cell line, engineered to disrupt the expression of the ARFGAP2 gene. This polyclonal pool provides a genetically heterogeneous loss-of-function model, enabling robust investigation of ARFGAP2-dependent cellular processes without the clonal selection bias of single-cell isolates.
The Jurkat cell line is an immortalized human T lymphocyte originally derived from the peripheral blood of a 14-year-old male with acute T-cell leukemia. Widely employed as a model for T-cell signaling, apoptosis, and leukemia biology, Jurkat cells exhibit characteristic T-cell receptor (TCR) activation pathways and provide a well-characterized system for studying membrane trafficking and signal transduction in a leukemic context.
ARFGAP2 encodes a GTPase-activating protein that stimulates GTP hydrolysis on ADP-ribosylation factor 1 (ARF1), a central regulator of COPI vesicle coat dynamics. ARFGAP2 interacts with the COPI coatomer complex (??-COP, ??-COP), membrane-associated factors like phosphoinositides, and the p24 cargo receptor family. By triggering GTP hydrolysis on ARF1, ARFGAP2 promotes COPI coat disassembly, enabling cargo sorting and vesicle uncoating during retrograde transport from the Golgi to the ER. Downstream, this activity recycles KDEL receptors and retains Golgi-resident enzymes. ARF1 and the COPI complex act upstream, with membrane curvature co-regulating GAP activity. Additional partners include ERGIC-53 and Rab GTPases (Rab1, Rab2), which coordinate ERGIC organization and vesicle tethering, embedding ARFGAP2 in an essential trafficking network for Golgi homeostasis and protein quality control.
In Jurkat T cells, proper Golgi function is essential for membrane receptor trafficking, cytokine secretion, and cell surface protein presentation, which directly impact T-cell activation and signaling. Disruption of ARFGAP2 and the ensuing dysregulation of COPI-dependent retrograde transport may impair the recycling of key receptors and signaling molecules, potentially altering TCR complex assembly and downstream signal transduction pathways. This model is thus particularly relevant for studying how defects in membrane trafficking contribute to leukemic T-cell phenotypes, Golgi apparatus dysfunction, and the pathogenesis of T-cell malignancies.
Researchers can employ this ARFGAP2 knockout Jurkat polyclonal population to investigate COPI vesicle trafficking, ARF1 regulatory mechanisms, and Golgi-to-ER retrograde transport in a T-cell context. Representative assays include Western blotting for ARFGAP2 and COPI subunits (??-COP, ??-COP), immunofluorescence staining for Golgi markers (GM130, giantin) to assess organelle morphology, retrograde transport assays using KDEL receptor cycling, and RT-qPCR for Golgi stress response genes. Additionally, flow cytometry can be used to monitor changes in surface receptor levels (e.g., TCR components) and cell viability under stress conditions, making this knockout model a versatile tool for cancer cell biology and the study of membrane protein localization. For further information, please contact Ascent Research.
